IRIDEX Corporation
1.0300+0.02 (+1.98%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · IRIX · USD
Key Stats
Market Cap
17.50MP/E (TTM)
-Basic EPS (TTM)
-0.32Dividend Yield
0%Recent Filings
8-K
Iridex regains Nasdaq compliance
Iridex Corporation regained Nasdaq compliance on August 27, 2025, after satisfying the $2,500,000 stockholders' equity minimum under Listing Rule 5550(b)(1), based on its Q2 2025 10-Q filed August 12. This resolves the non-compliance flagged in May from Q1 results. Compliance secured. The closure stabilizes listing status amid ophthalmology market pressures.
8-K
IRIDEX Q2 revenue rises 7%
IRIDEX Corporation reported Q2 2025 revenue of $13.6 million, up 7% year-over-year, fueled by 10% growth in retina products to $8.0 million while Cyclo G6 stayed flat at $3.3 million. Operating expenses dropped 28% to $5.6 million, yielding a net loss of $1.0 million and positive adjusted EBITDA of $21 thousand—its third straight quarter. Cash dipped to $6.8 million. The firm targets cash flow breakeven and positive adjusted EBITDA for 2025, matching 2024 revenue levels. Progress builds momentum.
10-Q
Q2 FY2025 results
IRIDEX posted Q2 revenue of $13.6M, up 7.4% y/y from $12.6M, with retina sales jumping 10.3% to $8.0M while glaucoma dipped 1.3%; gross margin slipped to 34.5% from 40.7% on higher manufacturing costs and international mix. Operating loss narrowed to $0.9M from $2.6M, thanks to 42% cuts in R&D and 27% in sales/marketing, though net loss widened slightly to $1.0M from $2.7M due to $1.3M debt extinguishment hit in Q1. Cash climbed to $6.8M on $10M from preferred stock and notes, minus Lind payoff; free cash flow not disclosed in the 10-Q. Topcon drove 32% of sales. Yet competition from rival laser techs lingers.
8-K
IRIDEX approves share boosts
IRIDEX stockholders approved key governance updates at the June 11, 2025 annual meeting, boosting authorized common shares to 63.5 million while modernizing the charter. They also expanded the 2008 Equity Incentive Plan by 1 million shares, extending it to 2035 to fuel talent retention. Directors were elected; BPM LLP ratified as auditors. This bolsters flexibility for growth, yet dilutes existing holders.
8-K
IRIDEX amends investor rights
IRIDEX Corporation amended its Investor Rights Agreement with Novel Inspiration International Co., Ltd. on May 20, 2025, restricting asset sales of a substantial but not substantially all portion without unanimous board consent, unless to a wholly-owned subsidiary. This tightens governance amid the March 19, 2025 original pact. No financial terms disclosed. It curbs flexibility yet bolsters oversight.
ALC
Alcon Inc.
73.60-1.22
ESMC
Escalon Medical Corp.
0.15+0.00
GKOS
Glaukos Corporation
77.09-0.70
IRMD
iRadimed Corporation
78.31-1.48
IRME
IR-Med Inc.
0.03+0.00
MASI
Masimo Corporation
142.91-3.50
QTRX
Quanterix Corporation
5.17-0.31
RTGN
RETINALGENIX TECHNOLOGIES INC
3.75+0.00
RXST
RxSight, Inc.
8.43-0.38
SGHT
Sight Sciences, Inc.
5.04-0.13